Calendar

««Dec 2008»»
SMTWTFS
 
1
2
3
4
56
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate



Link to Ai profile Link to Anxiety Community Link to Wellsphere

Health Wisdom

HealthCentral Top Site Award

IBS Tales Hope Award

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

recommended links

Depression is Real's Down & Up Show
      Weekly audio-casts from the
      Depression Is Real Coalition

we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 1,935,735
since: 14 May 2006

Neurogenesis promoting compound begins Phase II trial for anxious depression

posted Saturday, 19 April 2008

Neurogenesis antidepressants

San Diego-based drug discovery and development company BrainCells Inc. has begun a Phase IIa clinical trial of its innovative depression with anxiety drug, BCI-540.

"We are encouraged by the enthusiasm expressed by our clinical investigators who view BCI-540 as a potential alternative to today's widely prescribed treatments for depression," noted Carrolee Barlow, M.D., Ph.D., Chief Scientific Officer at BCI. "Current therapies directly impact serotonin levels causing many unpleasant side effects, however we have shown that BCI-540 directly impacts neurogenesis without affecting serotonin levels. We are excited about the potential of this compound to change the way mood disorders are treated."

Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. It is thought that most current antidepressants encourage formation of new neurons in the hippocampus by neurogenesis. However, BCI-540 does not act upon serotonin, norepinephrine (noradrenaline), or dopamine pathways as traditional antidepressants do. A previous 6-months trial of the compound for a non psychiatric disorder found side-effects did not differ from those produced by the placebo control.

The twelve-week randomized double-blind, placebo-controlled study will evaluate safety, efficacy and tolerability of BCI-540 to determine whether 80 mg given once or three times daily is effective in the treatment of depression with anxiety versus placebo.

BrainCells Inc in-licensed BCI-540 from Mitsubishi Pharmaceutical Corporation in August 2006.

tags:  

links: digg this    del.icio.us    technorati    reddit